Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The implication of the presence of tumor-infiltrating T lymphocytes (TIL-T) in diffuse large B-cell lymphoma (DLBCL) is yet to be elucidated. We aimed to investigate the effect of TIL-T levels on the prognosis of patients with DLBCL.Methods: Ninety-six patients with DLBCL were enrolled in the study. The TIL-T ratio was measured using QuPath, a digital pathology software package. The TIL-T ratio was investigated in three foci (highest, intermediate, and lowest) for each case, resulting in TIL-T–Max, TIL-T–Intermediate, and TIL-T–Min. The relationship between the TIL-T ratios and prognosis was investigated.Results: When 19% was used as the cutoff value for TIL-T–Max, 72 (75.0%) and 24 (25.0%) patients had high and low TIL-T–Max, respectively. A high TIL-T–Max was significantly associated with lower serum lactate dehydrogenase levels (p < .001), with patient group who achieved complete remission after RCHOP therapy (p < .001), and a low-risk revised International Prognostic Index score (p < .001). Univariate analysis showed that patients with a low TIL-T–Max had a significantly worse prognosis in overall survival compared to those with a high TIL-T–Max (p < .001); this difference remained significant in a multivariate analysis with Cox proportional hazards (hazard ratio, 7.55; 95% confidence interval, 2.54 to 22.42; p < .001).Conclusions: Patients with DLBCL with a high TIL-T–Max showed significantly better prognosis than those with a low TIL-T–Max, and the TIL-T–Max was an independent indicator of overall survival. These results suggest that evaluating TIL-T ratios using a digital pathology system is useful in predicting the prognosis of patients with DLBCL.
Abstract
Background: The implication of the presence of tumor-infiltrating T lymphocytes (TIL-T) in diffuse large B-cell lymphoma (DLBCL) is yet to be elucidated. We aimed to investigate the effect of TIL-T levels on the prognosis of patients with DLBCL.Methods: Ninety-six patients with DLBCL were enrolled in the study. The TIL-T ratio was measured using QuPath, a digital pathology software package. The TIL-T ratio was investigated in three foci (highest, intermediate, and lowest) for each case, resulting in TIL-T–Max, TIL-T–Intermediate, and TIL-T–Min. The relationship between the TIL-T ratios and prognosis was investigated.Results: When 19% was used as the cutoff value for TIL-T–Max, 72 (75.0%) and 24 (25.0%) patients had high and low TIL-T–Max, respectively. A high TIL-T–Max was significantly associated with lower serum lactate dehydrogenase levels (p < .001), with patient group who achieved complete remission after RCHOP therapy (p < .001), and a low-risk revised International Prognostic Index score (p < .001). Univariate analysis showed that patients with a low TIL-T–Max had a significantly worse prognosis in overall survival compared to those with a high TIL-T–Max (p < .001); this difference remained significant in a multivariate analysis with Cox proportional hazards (hazard ratio, 7.55; 95% confidence interval, 2.54 to 22.42; p < .001).Conclusions: Patients with DLBCL with a high TIL-T–Max showed significantly better prognosis than those with a low TIL-T–Max, and the TIL-T–Max was an independent indicator of overall survival. These results suggest that evaluating TIL-T ratios using a digital pathology system is useful in predicting the prognosis of patients with DLBCL.
참고문헌 (26)
- Alaggio R, "The 5th edition of the World Health Organization classification of haematolymphoid tumours : lymphoid neoplasms", Leukemia, 36, pp.1720~1748 (2022)
- Campo E, "The International Consensus Classification of Mature Lymphoid Neoplasms : a report from the Clinical Advisory Committee", Blood, 140, pp.1229~1253 (2022)
- Younes A, "Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma", J Clin Oncol, 37, pp.1285~1295 (2019)
- Davies A, "Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma(REMoDL-B) : an open-label, randomised, phase 3 trial", Lancet Oncol, 20, pp.649~662 (2019)
- Nowakowski GS, "ROBUST : a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma", J Clin Oncol, 39, pp.1317~1328 (2021)
- Zhang J, "Cancer immunotherapy in diffuse large B-cell lymphoma", Front Oncol, 8, pp.351~ (2018)
- Wang L, "New agents and regimens for diffuse large B cell lymphoma", J Hematol Oncol, 13, pp.175~ (2020)
- Nicholas NS, "Tumor microenvironment(TME)-driven immune suppression in B cell malignancy", Biochim Biophys Acta, 1863, pp.471~482 (2016)
- Scott DW, "The tumour microenvironment in B cell lymphomas", Nat Rev Cancer, 14, pp.517~534 (2014)
- Fridman WH, "The immune contexture in human tumours : impact on clinical outcome", Nat Rev Cancer, 12, pp.298~306 (2012)
- Keane C, "Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma : a population-based study", Lancet Haematol, 2, pp.e445~e455 (2015)
- Xu-Monette ZY, "Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL", Cancer Immunol Res, 7, pp.644~657 (2019)
- Sermer D, "Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies", Blood Adv, 4, pp.4669~4678 (2020)
- Hopfinger G, "CAR-T cell therapy in diffuse large B cell lymphoma : hype and hope", Hemasphere, 3, pp.e185~ (2019)
- Xu Y, "Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma : a multiparameter flow cytometry study", Br J Haematol, 112, pp.945~949 (2001)
- Lippman SM, "Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course", Mod Pathol, 3, pp.361~367 (1990)
- Keane C, "CD4(+)tumor infiltrating lymphocytes are prognostic and independent of RIPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy", Am J Hematol, 88, pp.273~276 (2013)
- Ansell SM, "Cd4+ T-cell immune response to large B-cell non-Hodgkin’s lymphoma predicts patient outcome", J Clin Oncol, 19, pp.720~726 (2001)
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Sehn LH, "The revised International Prognostic Index(R-IPI)is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP", Blood, 109, pp.1857~1861 (2007)
- Bankhead P, "QuPath : Open source software for digital pathology image analysis", Sci Rep, 7, pp.16878~ (2017)
- Wang S, "Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction", Elife, 8, pp.e4020~ (2019)
- Blankenstein T, "The determinants of tumour immunogenicity", Nat Rev Cancer, 12, pp.307~313 (2012)
- Mukhopadhyay S, "Whole slide imaging versus microscopy for primary diagnosis in surgical pathology : a multicenter blinded randomized noninferiority study of 1992 cases(pivotal study)", Am J Surg Pathol, 42, pp.39~52 (2018)
- Gudlaugsson E, "Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer", Histopathology, 61, pp.1134~1144 (2012)
- Stalhammar G, "Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer", Histopathology, 72, pp.974~989 (2018)